We Update you with the Clock Running. Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explains Patient Family Education and Rights.
Theravance Announces Positive Phase 2 Clinical Results In The MABA Respiratory Program For The Treatment Of COPD
Asthma / Respiratory Theravance, Inc. (NASDAQ: THRX) announced the positive results from a Phase 2 study of the lead investigational compound GSK961081 ('081) in the inhaled bifunctional muscarinic antagonist-beta2 agonist (MABA) program. The MABA program was licensed to GlaxoSmithKline (GSK) in 2005 under the terms of the companies' Strategic Alliance Agreement as a potential treatment for patients with chronic obstructive pulmonary disease (COPD).
Custom Search
